Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Benzinga.com6h
Peering Into Gilead Sciences's Recent Short Interest
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
FierceBiotech6h
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
FiercePharma3d
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
PharmiWeb4d
Non-Alcoholic Steatohepatitis Clinical Trials Market Projected Growth to Reach USD 5.1 Billion by 2032 at a 7% of CAGR
However, the market is expected to grow significantly between 2022 and 2032, with a projected growth rate of 7%, which is ...
stocknews6d
3 Biotech Stocks Set to Revolutionize Medicine
The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...
Daily Maverick on MSN7d
Efficacy of six-monthly HIV prevention jab confirmed in second major study
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
AllAfrica.com7d
South Africa: Efficacy of 6-Monthly HIV Prevention Jab Confirmed in Second Major Study
In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.